← All organizations
Highest phase reached
Phase 4
Timeline
2010s
- Jun 1, 2012
Axsome Therapeutics, Inc.— Founded
- Mar 20, 2019
solriamfetol— Marketing Organization
2020s
- Aug 18, 2022
bupropion— NDA Secondary Org
Drugs by trial phase (9 distinct, 30 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (6 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Cataplexy
- Complex Regional Pain Syndromes
- Dementia
- Depression
- Depressive Disorder
- Depressive Disorder, Treatment-Resistant
- Disease
- Major Depressive Disorder
- Migraine Disorders
- Narcolepsy
- Osteoarthritis
- Osteoarthritis, Knee
- Psychomotor Agitation
- Reflex Sympathetic Dystrophy
- Sleepiness
- Syndrome
- Tobacco Use Disorder
Marketed drugs (3)
Recent trials (30)
- NCT06878976Lead sponsorPhase 3Feb 20, 2025
- NCT06736509Lead sponsorPhase 3Nov 21, 2024
- NCT06568367Lead sponsorPhase 3Aug 1, 2024
- NCT06413433Lead sponsorPhase 3Apr 26, 2024
- NCT06360419Lead sponsorPhase 3Mar 18, 2024
- NCT06170970CollaboratorPhase 2Mar 1, 2024
- NCT06223880Lead sponsorPhase 4Dec 27, 2023
- NCT05838430CollaboratorPhase 4Jul 31, 2023
- NCT05972044Lead sponsorPhase 3Jul 6, 2023
- NCT05557409Lead sponsorPhase 3Sep 6, 2022
- NCT05550207Lead sponsorPhase 3Aug 31, 2022
- NCT05113745Lead sponsorPhase 3Oct 20, 2021
- NCT05059223Lead sponsorPhase 3Sep 15, 2021
- NCT04947553Lead sponsorPhase 3Jun 17, 2021
- NCT04971291Lead sponsorPhase 2Apr 14, 2021
Details
- Founded
- New York, NY, US Jun 1, 2012
- Last known activity
- Feb 20, 2025